Elmar Schnee
Elmar Schnee
Born 1959. Board member since 2019.
Education:
Master’s degree in marketing and management from SIB.
Board Committees:
Chairman of the Remuneration Committee.
Experience:
Elmar Schnee was previously CEO of Merck Serono and was instrumental in the acquisition of Serono by Merck KGaA. He has also served as General Partner and member of the Executive Board of Merck KGaA and has held previously several senior global management positions with UCB and Sanofi.
Other current assignments:
Chairman of the board of directors of ProCom Rx SA, Moleac Pte Lts and Noorik Biopharmaceuticals AG as well as a member of the board of directors of Kuste Biopharma, Mindmaze SA and Damian Pharma AG.
Holdings in the Company:
Elmar Schnee holds 33,236 shares in the company, 14,063 share awards in LTIP 2020, 10,624 share awards in LTIP 2021 and 13,926 share awards in LTIP 2022.
Independent in relation to the Company and its management and in relation to major shareholders.
Elisabeth Björk
Elisabeth Björk
Born 1961. Board member since 2022.
Education:
MD degree, Karolinska Institute, Stockholm and Associate Professor, Medicine, Uppsala University
Board Committees:
Member of the Remuneration Committee.
Experience:
Elisabeth Björk is an endocrinologist by training and an associate professor of medicine at Uppsala University, Sweden. Elisabeth Björk is the Senior Vice President, Head of Late-stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D at AstraZeneca leading the global development of medicines within this area. Throughout her career at AstraZeneca, she has gained broad drug development experience covering clinical development phase I-IV, large outcomes programs, major global filings and health authority interactions (FDA, EMA, Japan) and commercial strategy/implementation.
Other current assignments:
Board member in Rocket Pharmaceuticals, Pharvaris NV, Chalmers University of Technology, Chalmers Ventures.
Holdings in the Company:
Elisabeth Björk holds 5,356 share awards in LTIP 2022.
Independent in relation to the Company and its management and in relation to major shareholders.
Fred Driscoll
Fred Driscoll
Born 1950. Board member since 2023.
Education:
B.S. Accounting, Bentley University.
Board Committees:
–
Experience:
Mr. Driscoll has served as Interim Chief Financial Office at Invivyd, Inc. from Oct. 2022 to May 2023. Since May 2021 until Nov. 2021, Mr. Driscoll served as Chief Financial Officer at Flexion Therapeutics which was acquired by Pacira Biosciences, a role he previously served from 2013 to 2017, spearheading the initial public offering in 2014. Prior to joining Flexion Therapeutics, he was Chief Financial Officer at Novavax, Inc., a publicly traded biopharmaceutical company, from 2009 to 2013. From 2008 to 2009, Mr. Driscoll served as Chief Executive Officer of Genelabs Technologies, Inc., a publicly traded biopharmaceutical and diagnostics company later acquired by GlaxoSmithKline. He previously served as Genelabs’ Chief Financial Officer from 2007 to 2008. From 2003 to 2006, Mr. Driscoll served as Chief Executive Officer at OXiGENE, Inc., a biopharmaceutical company and from 2000 to 2003 as Chief Financial Officer. Mr. Driscoll has also served as Chairman of the Board and Audit Committee Chair at OXiGENE and as a member of the Audit Committee for Cynapsus, which was sold to Sunovion Pharmaceuticals in 2016.
Other current assignments:
Mr. Driscoll currently serves as a board member for Cellectar BioSciences, Cue BioPharma and MEI Pharma.
Holdings in the Company:
None.
Independent in relation to the Company and its management and in relation to major shareholders.
Hilde Furberg
Hilde Furberg
Born 1958. Board member since 2014.
Education:
Master of Science in Engineering from Oslo University, Norway.
Board Committees:
Member of the Audit Committee.
Experience: Hilde Furberg is an independent consultant and professional Board member. She has extensive experience of leadership from her 35 years in sales, marketing, strategy and management in Pharma / Biotech. Her experience is in various fields of rare diseases, which she gained working in small companies and large global corporations. Hilde has worked in companies such as Genzyme and Baxter, she was most recently SVP and General Manger / European Head of Rare Diseases at Sanofi Genzyme. In addition to working for Genzyme / Sanofi Genzyme, Hilde has since 2005 worked as non-executive director and Board member of Probi, Pronova, Clavis, Bergenbio and Algeta.
Other current assignments:
She is currently an industrial advisor to Investinor and Board member of PCI Biotech, Herantis Pharma, Sedana Medical, Bio-Me and Pluvia Biotech.
Holdings in the company:
Hilde Furberg holds 53,199 shares in the company, 4,327 share awards in board LTIP 2020, 4,086 share awards in LTIP 2021 and 5,356 share awards in LTIP 2022.
Independent in relation to the Company and its management and in relation to major shareholders.
Diane Parks
Diane Parks
Born 1952. Board member since 2019.
Education:
Master’s degree from Kansas State University and an MBA from Georgia State University.
Board Committees:
Member of the Remuneration Committee.
Experience:
Diane Parks is a senior executive with deep sales and marketing experience from the US, where she has held positions such as Head of US Commercial for Kite Pharma, VP of Sales for Amgen and Head of Global Marketing at Pharmacyclics.
Other current assignments:
Board member in CTI BioPharma, TriSalus Life Sciences, Kura Oncology, Soligenix and Celularity.
Holdings in the Company:
Diane Parks holds 8,499 shares in the company, 4,327 share awards in board LTIP 2020, 4,086 share awards in LTIP 2021 and 5,356 share awards in LTIP 2022.
Independent in relation to the Company and its management and in relation to major shareholders.
Henrik Stenqvist
Henrik Stenqvist
Born 1967. Board member since 2022.
Education:
Degree in Finance and Business Administration, University of Linköping
Board Committees:
Chairman of the Audit Committee.
Experience:
Henrik Stenqvist has served as CFO of several listed life science companies and currently, he is the CFO of SOBI. Previous positions include CFO at Recipharm, CFO at Meda, Regional Finance Director at AstraZeneca, Finance Director at Astra Export & Trading and Board member of MedCap AB.
Other current assignments:
Board member in Midsona AB.
Holdings in the company:
Henrik Stenqvist holds 10,000 shares in Calliditas and 5,356 share awards in LTIP 2022.
Independent in relation to the Company and its management and in relation to major shareholders.
For more information on the incentive programs, see section Remuneration.